ASH 2024: Changing the Treatment Landscape in Lymphoma
Research presented at ASH 2024 has shed new light on treatment strategies for mantle cell lymphoma and follicular lymphoma.
Related Articles
FDA Approves Cosibelimab for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative…
FLOT Combination Takes the Lead in Localized GE Cancer
2024 saw the establishment of docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil as the preferred regimen for patients with localized adenocarcinoma.
Tirzepatide May Increase AEs in HR+/HER2– Breast Cancer Treatment
The FITWISE clinical trial assessed the safety and tolerability of breast cancer treatments when patients use tirzepatide.
JAB-8263 Monotherapy Demonstrates Early Promise in Myelofibrosis
JAB-8263 given at once-daily doses ranging from 0.125 mg to 0.3 mg proved to be well tolerated in patients with myelofibrosis.
Recurrence-Free Interval Is Longer With Low ctDNA Levels at Baseline in TNBC
ctDNA was most frequently detected within 6 months post-treatment in patients with TNBC, aligning with the early recurrence pattern characteristic of the disease.
Effects of the Oncology Industrial Complex on Academic Cancer Centers
This Viewpoint outlines the missions of academic cancer centers and how they are being affected by the oncology industrial complex along with challenges and suggestions…
Major shake-up for hospital bookings and test results sent to your phone
NHS patients will soon be able to choose when and where they are treated in a new Deliveroo-style app. Ministers are overhauling the NHS app…
Perioperative Atezolizumab Plus Chemo Does Not Improve EFS in TNBC
Treatment with atezolizumab and neoadjuvant chemotherapy followed by adjuvant atezolizumab did not improve EFS in triple-negative breast cancer.